Genmab is an international biotechnology company based in Denmark, focused on developing fully human antibody therapeutics for the potential treatment of cancer. The company’s pipeline of fully human antibodies currently consists of 7 products in clinical development as well as numerous pre-clinical programs and other disease targets under exploration. Genmab holds partnerships with Amgen Inc., Bionomics Limited, GlaxoSmithKline, Medarex and Roche.